• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

    11/14/24 4:05:00 PM ET
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRO alert in real time by email

    Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025

    Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M

    CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.

    "Enrollment in the Phase 3 tebipenem HBr trial is progressing well, and we are on track to complete enrollment in the second half of 2025. Further, our work on the Phase 2 ready SPR206 program continues, contingent on availability of non-dilutive funding," said Sath Shukla, President and Chief Executive Officer of Spero. "With SPR720 development plans now suspended while we complete a review of the full dataset from the Phase 2a trial, our extended cash runway into mid-2026 and streamlined operations position us well to achieve our ultimate goal of delivering new therapies to patients in need."

    Pipeline Update

    Tebipenem HBr

    Tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI) including acute pyelonephritis (AP) to help patients potentially avoid hospitalizations or reduce duration of in-patient therapy. Spero granted GSK an exclusive license to commercialize tebipenem HBr in all territories, except certain Asian territories.

    • Enrollment on track in PIVOT-PO, the global Phase 3 clinical trial of tebipenem HBr in patients with cUTI. This randomized, double-blinded trial compares oral tebipenem HBr with intravenous imipenem cilastatin, in hospitalized adult patients with cUTI/AP. The primary endpoint is overall response (a combination of clinical cure and favorable microbiological response) at the Test-of-Cure (TOC) visit. Target enrollment for the trial is approximately 2,648 patients, with enrollment completion expected in the second half of 2025. For more information on PIVOT-PO, refer to ClinicalTrials.gov ID NCT06059846.

    SPR206

    SPR206 is an investigational, intravenously administered next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa in preclinical studies.

    • The U.S. Food and Drug Administration (FDA) has cleared the Company's IND for a Phase 2 trial in patients with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP). The Company maintains its guidance to initiate the trial contingent on availability of non-dilutive funding.

    SPR720

    SPR720 is an investigational oral, chemically stable phosphate ester prodrug that is converted rapidly in vivo to SPR719, the active moiety. SPR719 targets the ATPase site of DNA gyrase B in mycobacteria.

    • In October 2024, a planned interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD) demonstrated that the study did not meet its primary endpoint. While the data showed antimicrobial activity associated with SPR720, the interim analysis did not show sufficient separation from placebo and highlighted potential dose limiting safety issues in patients dosed at 1,000 mg orally once daily, including three cases of reversible grade 3 hepatotoxicity. In evaluating the totality of both the efficacy and safety data, the Company suspended its development program for SPR720 and will evaluate other potential paths forward as the remaining data are collected and analyzed.

    Corporate Update

    • In October 2024, following suspension of the current SPR720 development plans, Spero underwent a restructuring and reduction in force of approximately 39%, which extended the Company's cash runway into mid-2026.

    Third quarter 2024 Financial Results

    • Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September 30, 2024, compared with a net loss of $3.2 million, or ($0.06) per share of common stock, basic and diluted, for the third quarter ending September 30, 2023.
    • Total revenue for the third quarter of 2024 was $13.5 million, compared with total revenue of $25.5 million for the third quarter of 2023. The revenue decrease for the third quarter of 2024 was primarily due to lower revenues related to ongoing collaborations.
    • Research and development expenses for the third quarter of 2024 were $26.9 million, compared to $16.4 million of research and development expenses for the same period in 2023. The increase in research and development expenses year-over-year was primarily due to increased clinical trial expenses for PIVOT-PO.
    • General and administrative expenses for the third quarter of 2024 were $5.2 million, compared to $5.7 million of general and administrative expenses for the same period in 2023. This year-over-year decrease was primarily due to decreased consulting and professional expenses.
    • As of September 30, 2024, Spero had cash and cash equivalents of $76.3 million. Following the reduction in force and restructuring described above, Spero estimates that its existing cash and cash equivalents, together with earned and non-contingent development milestone payments from GSK, as well as other non-dilutive funding commitments, will be sufficient to fund its operating expenses and capital expenditures into mid-2026.

    For further details on Spero's financials, refer to Spero's Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (SEC) today.

    About Spero Therapeutics

    Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com

    Government Agency Research Support

    The views expressed in this press release are those of the authors and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

    Tebipenem HBr Research Support

    Select tebipenem HBr studies have been funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number HHSO100201800015C.

    Department of Defense

    Select SPR206 studies are supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Joint Warfighter Medical Research Program under Award No. W81XWH 19 1 0295. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

    National Institute of Allergy and Infectious Disease

    Select SPR206 studies have been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00022.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the timing, progress and results of Spero's preclinical studies, clinical trials and research and development programs; the potential benefits of any of Spero's current or future product candidates in treating patients; and Spero's strategy, goals and anticipated financial performance, milestones, business plans and focus. In some cases, forward-looking statements may be identified by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intent," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms or other similar expressions. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual results to differ materially from those indicated by such forward looking statements, including whether tebipenem HBr, SPR720 and SPR206 will advance through the clinical trial process on a timely basis, or at all, taking into account the effects of possible regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, clinical trial design and clinical outcomes; whether the results of such trials will warrant submission for approval from the FDA or equivalent foreign regulatory agencies; whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr; whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero's reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; Spero's need for additional funding; the ability to commercialize Spero's product candidates, if approved; Spero's ability to retain key personnel; Spero's leadership transitions; whether Spero's cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the "Risk Factors" set forth in filings that Spero periodically makes with the SEC. The forward-looking statements included in this press release represent Spero's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Spero explicitly disclaims any obligation to update any forward-looking statements.

    Investor Relations Contact:

    Shai Biran, PhD

    Spero Therapeutics

    [email protected]

    Media Inquiries:

    [email protected]

     
    Spero Therapeutics, Inc.
    Condensed Consolidated Balance Sheet Data
    (in thousands)
    (Unaudited)
        
     September 30, December 31,
      2024  2023
    Cash and cash equivalents$76,290  $76,333
    Other assets 58,871  106,057
    Total assets$ 135,161   $ 182,390
        
    Total liabilities 69,654   75,496
    Total stockholder's equity 65,507  106,894
    Total liabilities and stockholders' equity$ 135,161  $ 182,390



    Spero Therapeutics, Inc.
    Condensed Consolidated Statements of Operations
    (in thousands, except share and per share data)
    (unaudited)
            
     Three Months Ended

    September 30,
     Nine Months Ended

    September 30,
      2024   2023   2024   2023 
    Revenues:       
    Grant revenue$5,650  $2,091  $14,893  $5,349 
    Collaboration revenue - related party 7,754   23,164   17,721   24,200 
    Collaboration revenue 65   218   319   710 
    Total revenues 13,469   25,473   32,933   30,259 
    Operating expenses:       
    Research and development 26,864   16,393   67,921   34,883 
    General and administrative 5,198   5,708   16,648   19,121 
    Impairment of long-term asset —   5,306   —   5,306 
    Total operating expenses 32,062   27,407   84,569   59,310 
    Loss from operations (18,593)  (1,934)  (51,636)  (29,051)
    Other income (expense) 1,156   940   3,668   2,877 
    Net loss (17,437)  (994)  (47,968)  (26,174)
    Income tax expense 290   (2,211)  290   (2,211)
    Net loss$(17,147) $(3,205) $(47,678) $(28,385)
            
    Net loss per share attributable

    to common shareholders per share, basic and diluted
    $(0.32) $(0.06) $(0.89) $(0.54)
            
    Weighted average shares outstanding, basic and diluted: 54,124,862   52,710,280   53,869,824   52,603,709 


    Primary Logo

    Get the next $SPRO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SPRO

    DatePrice TargetRatingAnalyst
    12/20/2024$5.00Outperform → In-line
    Evercore ISI
    9/23/2022$2.00 → $8.00In-line → Outperform
    Evercore ISI
    10/1/2021Outperform → Perform
    Oppenheimer
    More analyst ratings

    $SPRO
    SEC Filings

    See more
    • SEC Form 8-K filed by Spero Therapeutics Inc.

      8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

      6/18/25 5:12:45 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

      5/28/25 7:12:40 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Spero Therapeutics, Inc. (0001701108) (Filer)

      5/13/25 4:49:23 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Spero Therapeutics downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Spero Therapeutics from Outperform to In-line and set a new price target of $5.00

      12/20/24 7:51:16 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Spero Therapeutics from In-line to Outperform and set a new price target of $8.00 from $2.00 previously

      9/23/22 7:52:34 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Spero Therapeutics from Outperform to Perform

      10/1/21 6:10:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

      If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs2Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero's development partner, GSK, intends to submit CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) and GSK plc (LSE/NYSE:GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigation

      5/28/25 7:00:00 AM ET
      $GSK
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

      Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into Q2 2026 CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31,

      5/13/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

      5/5/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mahadevia Ankit was granted 20,000 shares, increasing direct ownership by 3% to 709,866 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      6/16/25 8:32:05 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deshpande Milind was granted 20,000 shares, increasing direct ownership by 28% to 91,454 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      6/16/25 8:30:52 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jackson Scott Thomas was granted 20,000 shares, increasing direct ownership by 36% to 75,000 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      6/16/25 8:29:35 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

      4/28/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

      CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of Esther Rajavelu as Chief Financial Officer and Chief Business Officer. Ms. Rajavelu will succeed Stephen DiPalma, who has served as the company's Interim CFO since August 1, 2023. "We are thrilled to welcome Esther to the executive leadership team as our new CFO and CBO. Esther brings a proven track record in corporate finance, from both indus

      11/1/23 8:05:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

      BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

      9/12/23 8:00:00 AM ET
      $PTCT
      $SPRO
      $TCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $SPRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Spero Therapeutics Inc.

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      11/14/24 5:37:55 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Spero Therapeutics Inc.

      SC 13G - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/24 4:25:21 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Spero Therapeutics Inc. (Amendment)

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/23 11:47:54 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRO
    Financials

    Live finance-specific insights

    See more
    • Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

      5/5/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

      Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review and reprioritization of the Company's pipeline in Q1 2025 Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into

      3/27/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

      CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.   To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this li

      3/18/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care